Author: Lin Li; Ting Sun; Yufei He; Wendong Li; Yubo Fan; Jing Zhang
Title: Epitope-based peptide vaccine design and target site characterization against novel coronavirus disease caused by SARS-CoV-2 Document date: 2020_2_27
ID: e9vq3fe3_32
Snippet: In this study, we characterized the physio-chemical characteristics of SARS-CoV-2 viral genome for epitope candidates and adopted an immune-informatics based pipeline with highly stringent criteria to identify S protein targeted B-and T-cell epitopes that may potentially promote an immune response in the host. The antigenicity, flexibility, solvent accessibility, disulphide bonds of predicted epitopes were evaluated, yielding four potential B-cel.....
Document: In this study, we characterized the physio-chemical characteristics of SARS-CoV-2 viral genome for epitope candidates and adopted an immune-informatics based pipeline with highly stringent criteria to identify S protein targeted B-and T-cell epitopes that may potentially promote an immune response in the host. The antigenicity, flexibility, solvent accessibility, disulphide bonds of predicted epitopes were evaluated, yielding four potential B-cell epitope and vaccine candidate. Allergenicity and toxicity analysis confirmed the four B-cell epitopes are of non-allergen and non-toxin. Stability analysis revealed that they can not be digested by multiple enzymes. In addition, two MHC class-I and nine MHC class-II binding Tcell epitopes were predicted to interact with numerous HLA alleles and to be highly antigenic in nature.
Search related documents:
Co phrase search for related documents- immune response and multiple enzyme: 1
- immune response and non toxin: 1, 2
- immune response and predict epitope: 1, 2, 3, 4
- immune response and stability analysis: 1, 2, 3, 4, 5
- immune response and toxicity allergenicity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- immune response and vaccine candidate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- immune response and viral genome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- MHC class and non toxin: 1
- MHC class and predict epitope: 1, 2, 3, 4
- MHC class and stability analysis: 1, 2, 3, 4
- MHC class and toxicity allergenicity: 1, 2, 3, 4, 5, 6, 7
- MHC class and toxicity allergenicity analysis: 1, 2
- MHC class and vaccine candidate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- solvent accessibility and viral genome: 1, 2
- stability analysis and toxicity allergenicity: 1, 2, 3, 4, 5, 6
- stability analysis and toxicity allergenicity analysis: 1, 2, 3, 4
- stability analysis and vaccine candidate: 1, 2, 3, 4, 5
- toxicity allergenicity analysis and vaccine candidate: 1, 2
- toxicity allergenicity and vaccine candidate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Co phrase search for related documents, hyperlinks ordered by date